ProShare Advisors LLC Reduces Stake in Xencor, Inc. (NASDAQ:XNCR)

ProShare Advisors LLC lessened its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 20.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,805 shares of the biopharmaceutical company’s stock after selling 3,231 shares during the period. ProShare Advisors LLC’s holdings in Xencor were worth $242,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Parallel Advisors LLC raised its stake in Xencor by 303.9% during the fourth quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,015 shares during the period. GAMMA Investing LLC lifted its holdings in Xencor by 153.7% in the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,316 shares during the last quarter. SG Americas Securities LLC purchased a new position in Xencor in the second quarter worth approximately $154,000. XTX Topco Ltd acquired a new stake in Xencor during the second quarter worth $196,000. Finally, Acadian Asset Management LLC purchased a new stake in Xencor in the first quarter valued at $206,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Raymond James lowered their price target on Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a report on Friday, June 14th. JPMorgan Chase & Co. reduced their price target on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Royal Bank of Canada increased their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Wedbush reissued an “outperform” rating and issued a $34.00 target price on shares of Xencor in a research report on Monday, September 9th. Finally, BMO Capital Markets restated an “outperform” rating and set a $32.00 price target on shares of Xencor in a research report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.78.

Insider Buying and Selling

In other Xencor news, VP John R. Desjarlais sold 36,329 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total value of $665,547.28. Following the sale, the vice president now directly owns 192,319 shares of the company’s stock, valued at approximately $3,523,284.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.23% of the stock is owned by insiders.

Xencor Trading Up 1.9 %

NASDAQ:XNCR opened at $19.85 on Friday. Xencor, Inc. has a 12-month low of $15.31 and a 12-month high of $26.84. The firm has a market cap of $1.39 billion, a PE ratio of -9.06 and a beta of 0.67. The company has a current ratio of 6.92, a quick ratio of 6.92 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average price of $18.55 and a 200 day moving average price of $20.23.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The company had revenue of $16.96 million during the quarter, compared to analysts’ expectations of $21.13 million. During the same quarter in the previous year, the business posted ($0.37) EPS. The business’s quarterly revenue was down 62.7% compared to the same quarter last year. Sell-side analysts anticipate that Xencor, Inc. will post -4.15 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.